Tags

Type your tag names separated by a space and hit enter

A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Am J Obstet Gynecol. 1993 Nov; 169(5):1183-9.AJ

Abstract

OBJECTIVES

Our objective was to compare the effects of low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins on metabolic risk markers for coronary heart disease.

STUDY DESIGN

A cross-sectional comparison of 70 women who used a formulation that contained 30 micrograms ethinyl estradiol and 150 micrograms desogestrel, 43 women who used a formulation that contained 30 micrograms ethinyl estradiol and 75 micrograms gestodene, and 54 women who did not use steroidal contraceptives was performed.

RESULTS

Oral contraceptive users had higher concentrations of high-density lipoproteins than did women in the control group (+10% to +20%, p < 0.001) primarily because of increases in high-density lipoprotein subfraction 3. High-density lipoprotein subfraction 2 concentrations were higher in users of the desogestrel formulation. Low-density lipoprotein cholesterol concentrations were normal in oral contraceptive users, but triglyceride concentrations were high (+80% to +100%, p < 0.001). Fasting glucose, insulin, and C-peptide concentrations were similar in the three groups, but their responses to a glucose load were higher in oral contraceptive users than in controls (p < 0.01 to p < 0.001). The late plasma insulin response to glucose was higher in the women who used the gestodene formulation than in those who used the desogestrel formulation.

CONCLUSIONS

The metabolic profiles induced by these oral contraceptives were remarkably similar and may reflect the activity of the estrogen component.

Authors+Show Affiliations

Wynn Institute for Metabolic Research, London, England.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8238183

Citation

Crook, D, et al. "A Comparative Metabolic Study of Two Low-estrogen-dose Oral Contraceptives Containing Desogestrel or Gestodene Progestins." American Journal of Obstetrics and Gynecology, vol. 169, no. 5, 1993, pp. 1183-9.
Crook D, Godsland IF, Worthington M, et al. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol. 1993;169(5):1183-9.
Crook, D., Godsland, I. F., Worthington, M., Felton, C. V., Proudler, A. J., & Stevenson, J. C. (1993). A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. American Journal of Obstetrics and Gynecology, 169(5), 1183-9.
Crook D, et al. A Comparative Metabolic Study of Two Low-estrogen-dose Oral Contraceptives Containing Desogestrel or Gestodene Progestins. Am J Obstet Gynecol. 1993;169(5):1183-9. PubMed PMID: 8238183.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. AU - Crook,D, AU - Godsland,I F, AU - Worthington,M, AU - Felton,C V, AU - Proudler,A J, AU - Stevenson,J C, PY - 1993/11/1/pubmed PY - 1993/11/1/medline PY - 1993/11/1/entrez KW - Biology KW - Cardiovascular Effects KW - Cholesterol KW - Clinical Research KW - Comparative Studies KW - Contraception KW - Contraceptive Agents, Estrogen--pharmacodynamics KW - Contraceptive Agents, Female--pharmacodynamics KW - Contraceptive Agents, Progestin--pharmacodynamics KW - Contraceptive Agents--pharmacodynamics KW - Contraceptive Methods KW - Desogestrel--pharmacodynamics KW - Developed Countries KW - Diseases KW - England KW - Ethinyl Estradiol--pharmacodynamics KW - Europe KW - Family Planning KW - Gestodene--pharmacodynamics KW - Heart Diseases KW - Lipid Metabolic Effects KW - Lipids KW - Northern Europe KW - Oral Contraceptives KW - Oral Contraceptives, Low-dose KW - Physiology KW - Research Methodology KW - Research Report KW - Studies KW - United Kingdom SP - 1183 EP - 9 JF - American journal of obstetrics and gynecology JO - Am J Obstet Gynecol VL - 169 IS - 5 N2 - OBJECTIVES: Our objective was to compare the effects of low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins on metabolic risk markers for coronary heart disease. STUDY DESIGN: A cross-sectional comparison of 70 women who used a formulation that contained 30 micrograms ethinyl estradiol and 150 micrograms desogestrel, 43 women who used a formulation that contained 30 micrograms ethinyl estradiol and 75 micrograms gestodene, and 54 women who did not use steroidal contraceptives was performed. RESULTS: Oral contraceptive users had higher concentrations of high-density lipoproteins than did women in the control group (+10% to +20%, p < 0.001) primarily because of increases in high-density lipoprotein subfraction 3. High-density lipoprotein subfraction 2 concentrations were higher in users of the desogestrel formulation. Low-density lipoprotein cholesterol concentrations were normal in oral contraceptive users, but triglyceride concentrations were high (+80% to +100%, p < 0.001). Fasting glucose, insulin, and C-peptide concentrations were similar in the three groups, but their responses to a glucose load were higher in oral contraceptive users than in controls (p < 0.01 to p < 0.001). The late plasma insulin response to glucose was higher in the women who used the gestodene formulation than in those who used the desogestrel formulation. CONCLUSIONS: The metabolic profiles induced by these oral contraceptives were remarkably similar and may reflect the activity of the estrogen component. SN - 0002-9378 UR - https://www.unboundmedicine.com/medline/citation/8238183/A_comparative_metabolic_study_of_two_low_estrogen_dose_oral_contraceptives_containing_desogestrel_or_gestodene_progestins_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-9378(93)90279-R DB - PRIME DP - Unbound Medicine ER -